Outlook Therapeutics ($OTLK) Insider Trading & Smart Money Activity

Outlook Therapeutics, Inc. · Biotechnology · Latest filing Jun 11, 2026

Outlook Therapeutics, Inc. ($OTLK) has 2 analyst ratings on file.

Insider buyers (12 mo)

0

Insider sellers (12 mo)

0

Net insider $ (12 mo)

$0

Congress trades (12 mo)

0

13F moves on file

0

Analyst ratings on file

2

OTLK insider buying and selling by quarter

Quarter	Insider buys	Insider sales	Congress buys / sales	13F added / cut
Q1 2026	0	0	0 / 0	0 / 0
Q2 2026	0	0	0 / 0	0 / 0
Q3 2026	0	0	0 / 0	0 / 0
Q4 2026	0	0	0 / 0	0 / 0

Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.

All OTLK insider, congress, 13F and analyst activity

All Analysts

Date	Source	Who	Action	Shares	Value / amount	ΔOwn	1W	1M	6M	Filing	Story
Jun 11, 2026	Analyst	Ascendiant Capital	Reiterates to buy		PT $10		+43.6%	+40.9%			Read
Jun 11, 2026	Analyst	Ascendiant Capital	Reiterates to buy		PT $10		+43.6%	+40.9%			Read

1W / 1M / 6M = how OTLK moved from the trade or filing date.

Analyst ratings on OTLK

Date	Firm	Action	Rating	Price target	1W	1M	6M	Story
Jun 11, 2026	Ascendiant Capital	Reiterates	buy	$10	+43.6%	+40.9%		Read
Jun 11, 2026	Ascendiant Capital	Reiterates	buy	$10	+43.6%	+40.9%		Read

Other biotechnology stocks

• $HUMA
• $MNOV
• $RNA
• $SPRB
• $TNXP
• $CRBP
• $NBP
• $IMUX

Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.